Inovio has two flu vaccines at late stages of the product pipeline. Their VGX-3400 and its universal influenza vaccine have also shown positive results during development and trial stages. However, other companies like AVI BioPharma (AVII) and Antigenics (AGEN) might win the race for the first swine flu vaccine

CelSci’s preclinical studies on its Ligand Epitope Antigen Presentation System (LEAPS) have demonstrated that vaccines using this system have the potential to induce protection against the swine flu. Companies like GlazoSmithKline (GSK), AstraZeneca (AZN) and AVI Biopharma (AVII) are also developing alternatives for the swine flu vaccine and cures for the H1N1 virus.

The competitive advantage from top pharmaceutical companies has also been mimicked by the top biotech companies as the industry emerges as a leading player in the swine flu research. The swine flu pandemic is now recognized as one of the most profitable opportunities ever encountered by healthcare sector.

The most viable choices for investors are pharmaceutical companies with approved registration for H1N1 virus research that have vaccines with several phases into clinical trials. Top pharmaceutical companies and biotech companies with the largest distribution networks participating in the swine flu vaccine research and production include…

The right stock pick will clearly be based on a long term approach rather than on a get-rich-quick-scheme. A swine flu vaccine developed by any biotech companies will send their stocks soaring; you just have to look at their fundamentals, leave the gambling spirit on the side and focus on a long term investment strategy.